Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
1. Ɔvaviu
Slu-PP-332, we na sεntetik εstrojen rεsεptכr-rεlatεd כfεn rεsεptכr (ERR) agonist, kin gεt fayn ifekt pan mכtalman hεlth insay plεnti we dεm. frכm kεmikכl strכkchכral pεspεktiv, i de pan wan spεsifi k klas fכ sכm mכlikul kכmpawnd dεm we kin prεsis fכ biεn ERR rεsεpכta dεm, we de aktibכt wan siriכs fysiolojikal rispכns dεm. difrεnt frכm tradishכnal dכg כ mεtכd fכ rεgεl di bכdi fכnshכn, Slu-PP-332 de εksyεrt fysiolojikal rεguleshכn bay we i de tכk to di rεlatεvli nכvel ERR rεsεpכta.
Figure 1 Di kεmikכl strכkchכ fכ Slu-PP-332.
2. Mekanism fɔ Akshɔn
εnεji mεtabolism rεgulεshכn: Slu-PP-332 de sho sכm sכm rεgεdyushכn ifekt dεm pan εnεji mεtabolism. i de aktibכt di ERR rεsεpכta, we de εnhans di εnεji εkspεndishכn. na di sεl lεvεl, i de inkrεs di maytochכndrial fכnshכn εn i de impruv sεl rεspiretכri efyushכn, we de mek sεl dεm ebul fכ kכnvכlt nyutriεnt dεm to enεji mכr efyushכn. insay skel mכsul sεl dεm, Slu-PP-332 de indyuz di εksprεshכn fכ rilayt jin dεm, we de protεkt fεt asid כksidεshכn, we de alaw fεt fכ yuz mכr ful wan as enεji sכs εn ridyus fεt akyumyuleshכn. dis ifekt dεm de falamakata di bכdi in enεji mεtabolism we i de εksεsayz, we de mek di bכdi ebul fכ mεnten hכy lεvεl fכ εnεji ivin we i de rεst, we de εp fכ mεnten hεlty wet εn impruv di כvala mεtabolik stetכs.
impruv skel mכsul fכnshכn: We i kam pan skel mכsul, Slu-PP-332 de sho pכsitiv ifekt dεm. i kin aktibכt di akyu aerobik εksεsayz jεnεtik program, we dipכnt pan di ERRα rεsεpכta. stכdi dεn sho se afta dεn gi Slu-PP-332 to mays, inkrεs bin de pan di tayp IIa כksidεtiv skel mכsul fayb dεm, we de εnhans mכsul εndurans. di tayp IIa fayb dεm gεt hכy כksidεtiv kapasiti, we de mek i ebul fכ yuz כksijεn mכr efyushכn fכ prodyuz enεji, we de mek di mכsul aktiviti dεm de lכng. Fɔ mɔtalman, dis sho se Slu-PP-332 kin ɛp fɔ mek dɛn ebul fɔ bia wit ɛksɛsayz, we kin bɛnifit ɔl tu di atlet dɛn we de tray fɔ ɛp fɔ du mɔ ɛn di wan dɛn we de aim fɔ ɛp fɔ mek dɛn ebul fɔ du mɔ ɛvride. di εnhansmεnt we i de mek di skel mכsul mitochondrial fכnshכn kin εp bak fכ ridyus di mכsul dεm we de taya εn aksεlεrat di rεkכvεshכn afta di εksεsayz.
di kadyak fכnshכn mεntenans: di εstrojen rεsεpכta-rεlatεd כfεn rεsεpכta dεm ERRα εn ERRγ na di kכl rεgεlεt dεm fכ di kadyak mεtabolism. di mays dεm we nכ gεt ERRα εn ERRγ de divεlכp fεtal kadiomyopathy εn at fεil. as wan ifektiv ERR agonist, Slu-PP-332 de ple wan imכtant rol fכ mεnten di kadyak fכnshכn. Risach pipul dεm indyuz hat fεil in adכlt man mays via aortic coarctation (TAC) εn afta dat dεn administrεt Slu-PP-332 fכ tritmεnt. Slu-PP-332 tritmεnt sכmtεm improv di ejekshכn frakshכn fכ di mays, wan imכtant indikεtכ fכ kadyak pכmp fכnshכn, we indikεt εnhans kadyak kכntriktiliti. i bin impruv di maytochondrial ultrastructure bak, ridyus di kadyak fibrosis, εn nכmal di abnכmal εksprεshכn fכ di riletid jin dεm. dis chenj dεm we dεn kכlכv de kכntribyut fכ mek di at in nכmal strכkchכ εn fכ wok. Slu-PP-332 in impruvmεnt in kadyak fכnshכn de atribyut to in εnhansmεnt fכ di maytochכndrial fכnshכn εn rεguleshכn fכ fεt asid mεtabolism path dεm, we de gi nyu tεrapi we fכ at fεil.
3. Aplikeshɔn dɛn
Spɔt Mɛdisin Fil: Insay spɔt mɛrɛsin, Slu-PP-332 gɛt big pɔtnɛshɛl fɔ aplikeshɔn. Fɔ atlet dɛn, i kin bi nyu ejen we de ɛp fɔ mek dɛn pefɔmɛns bɛtɛ. We atlet dɛn kin ebul fɔ bia wit ɛksesaiz ɛn mek dɛn nɔ taya na dɛn mɔsul dɛn, dɛn kin ebul fɔ du mɔ fayn fayn wan we dɛn de tren ɛn we dɛn de kɔmpit. Di wan dɛn we de rɔn fɔ lɔng tɛm kin gɛt ɛkstend ɛksɛsayz ɛnjɔymɛnt limit ɛn impɔtant kɔmpitishɔn pefɔmɛns afta dɛn dɔn yuz am. Fɔ di wan dɛn we lɛk jenɛral fitnɛs, Slu-PP-332 kin ɛp dɛn fɔ gɛt mɔ efyushɔn stet fɔ ɛnaji mɛtabolism we dɛn de du ɛksɛsayz, fɔ mek dɛn ebul fɔ du ɛksɛsayz fayn fayn wan, fɔ ridyus di mɔsul dɛn we de sɔri afta dɛn dɔn du ɛksɛsayz ɛn ɔda tin dɛn we nɔ kin izi fɔ du, ɛn fɔ mek dɛn bɔdi wɛl, we kin mek dɛn ebul fɔ tek pat mɔ aktif wan pan ɛksɛsayz ɛn trenin. Fɔ di wan dɛn we nɔ ebul fɔ du ay-intensiti ɛksɛsayz bikɔs ɔf di fyzikal wok we de go dɔŋ, lɛk di wan dɛn we dɔn ol ɔ di wan dɛn we gɛt sɔm sik dɛn we nɔ de mɛn, Slu-PP-332 de mek di mɔsul dɛn wok fayn ɛn di ɛnaji mɛtabolism, we de mek dɛn ebul fɔ du mɔdaret ɛksɛsayz ɛn dat de mek dɛn kwaliti layf bɛtɛ.
mεtabolik sik tritmεnt: Insay di tritmεnt fכ mεtabolik sik dεm, Slu-PP-332 de sho bak se i gεt sכm sכmtin. If wi tek fat as ɛgzampul, i de mek dɛn spɛn mɔ ɛnaji ɛn i de ridyus di fat we de gɛda, ɛn dis de gi nyu tritmɛnt opshɔn fɔ di wan dɛn we fat. Prεklinik stכdi dεm sho se insay di it-indyuz obes mays כ ob/ob maws mכdel, administreshכn fכ Slu-PP-332 de ridyus bכdi wet fayn fayn wan εn impruv insulin sεnsitiviti. Dis na impɔtant tin bak fɔ di wan dɛn we gɛt tayp 2 dayabitis, bikɔs insulin rɛsistɛns na wan pan di men pathophysiological mɛkanism dɛm fɔ tayp 2 dayabitis. Slu-PP-332 de impruv insulin sεnsitiviti, we de εp fכ bεtε kכntrכl di blכd glukכs lεvεl. fכ pipul dεm we gεt mεtabolik sεndrכm, Slu-PP-332 kin kכmprεhεnsiv impruv mכltipכl mεtabolik dizכrd dεm, lεk dislipidemia εn haypatεnshכn, we de ridyus di risk fכ komplikεshכn lεk kכdivaskyul sik.
4. Fɔ dɔn
Hat sik prɛvɛnshɔn ɛn tritmɛnt: Given Slu-PP-332 in fayn fayn ifɛkt pan kadyak wok, i gɛt signifyant aplikeshɔn valyu na di fild fɔ hat sik prɛvɛnshɔn ɛn tritmɛnt. Fɔ di wan dɛn we gɛt at pwɛl, di tritmɛnt opshɔn dɛn we de naw nɔ bɔku, bɔt Slu-PP-332 de ɛp fɔ mek di kadyak wok fayn bay we i de ɛp fɔ mek di maytochondrial wok fayn ɛn i de rigul di fat asid mɛtabolism, we de gi nyu drɔg target fɔ di tritmɛnt we di at pwɛl. Fɔ pipul dɛm we de pan risk fɔ gɛt at sik, lɛk di wan dɛm we gɛt aypatɛnshɔn ɔ korona at sik, Slu-PP-332 kin ple wan prɛvɛntiv rol bay we i de mek di kadyak mɛtabolism ɛn wok fayn fayn wan, so dat i go ridyus di risk fɔ gɛt at sik. fכ sכmari, Slu-PP-332, as kכmpawnd wit wan yכnik mεkanism fכ akshכn, kin impruv di bכdi fכnshכn dεm.
Sos dɛn we dɛn pul
[1] Nasri H. Nyu op pan 'SLU-PP-332' as ifektiv ejen fɔ weit lɔs wit indaykt kidni protɛkshɔn ɛfifikɛshɔn; wan nεfrכlכji pכynt fכ si[J]. J ɔ rnal ɔ f Rεnal Ɛndokrinɔlɔji, 2024. Di s://api.semanticscholar.org/CorpusID:267189187. Di wan dɛn we de stɔdi bɔt di Baybul.
[2] Bilɔn C, Sitaula S, Banɛrji S, ɛn ɔda pipul dɛn. Wan Sεntetik ERR$alpha$ Agonist de Indyuz wan Akyu Aerobik Eksεsayz Rispכns εn εnhans Eksεsayz Kapasiti[J]. Biorxiv, 2022, ɛn ɔda pipul dɛn. https://api.semanticscholar.org/CorpusID:252819965, di wan dɛn we de stɔdi bɔt di Baybul.
[3] Xu W, Bilɔn C, Li H, ɛn ɔda pipul dɛn. Abstrakt 9682: Di Kadyak Protεktiv Efεkt dεm fכ Nכvεl Sεntetik Pan-Estrojen Rilatεd Rεsεptor Agonist Slu-pp-332 εn Slu-pp-915[J]. Sirkulεshכn, 2021,144.DOI:10.1161/circ.144.suppl_1.9682.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
